SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-20-095585
Filing Date
2020-08-14
Accepted
2020-08-14 16:32:51
Documents
1
Period of Report
2020-08-11

Document Format Files

Seq Description Document Type Size
1 3 a3.html 3  
1 3 a3.xml 3 4145
  Complete submission text file 0001104659-20-095585.txt   6407
Mailing Address LICHTSTRASSE 35 CH-4002 BASEL V8
Business Address LICHTSTRASSE 35 CH-4002 BASEL V8 212-830-2474
NOVARTIS PHARMA AG (Reporting) CIK: 0001030617 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36498 | Film No.: 201105653

Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Reporting) CIK: 0001114448 (see all company filings)

State of Incorp.: V8 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-36498 | Film No.: 201105652
SIC: 2834 Pharmaceutical Preparations

Mailing Address 209 PERRY PARKWAY SUITE 13 GAITHERSBURG MD 20877
Business Address 209 PERRY PARKWAY SUITE 13 GAITHERSBURG MD 20877 (301) 825 5320
Cellular Biomedicine Group, Inc. (Issuer) CIK: 0001378624 (see all company filings)

IRS No.: 861032927 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)